Compare DexCom, Inc. (DXCM) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Philip Morris International Inc. — how do they compare? DexCom, Inc. trades at $77.28 (market cap $28.06B), while Philip Morris International Inc. trades at $187.6 (market cap $281.91B). The key difference: Philip Morris International Inc. is far larger — about 10× DexCom, Inc.'s market cap, and Philip Morris International Inc. pays a 3.25% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | PM | |
|---|---|---|
Market Cap | $28.06B | $281.91B |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $191.86 |
52-Week Low | $54.84 | $144.33 |
Enterprise Value | $27.03B | $328.41B |
Dividend Yield | — | 3.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Philip Morris International (PM) trades at $175.95, down 2.35% amid a bearish technical signal and recent profit forecast revision. The company reported strong Q1 2026 EPS of $1.96, beating estimates, but faces headwinds from a $500 million impairment charge and margin pressures. Revenue growth remains steady, with 2025 revenue at $40.65 billion and net income margin of 26.74%. Analyst consensus is bullish with a $194 price target, though technical indicators show resistance near $179.
The stock presents a mixed outlook: solid fundamentals and high analyst buy ratings support upside potential, but near-term risks include cost pressures, currency volatility, and illicit market growth. Long-term investors may find value in the dividend and brand strength, while caution is warranted due to regulatory and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
